Stock fact sheet · data as of

NewGenIvf Group Limited (NIVF): fair value, margin of safety and Wheel Score

Healthcare · Medical - Care Facilities · Thailand · Value

Close0.2500
GLS fair value18,221.665 of 9 models
Margin of safety+100%price below fair value
Wheel Score39No optionscapped: no options
Health5/9Piotroski F-score
Moat3.6/10GLS 10-year score
Market cap$4K7.0M shares a day
Implied vol.-no listed options
P/E0.0EPS 560.25
Dividend yieldnone
Beta-0.04moves less than the market
Next earnings-no date recorded

Is NIVF undervalued?

NewGenIvf Group Limited (NIVF) closed at 0.2500 on 16 Oct 2026. The GLS average fair value - the simple average of the 5 valuation models that produced a positive number - is 18,221.66, which puts the price 100% below it. 5 of the 5 models value the shares above the current price. A gap this wide is rare in our universe of ~7,400 US stocks and is exactly what the Value part of the Wheel Score rewards; it is also where the question "why is it this cheap?" matters most.

There is a wide gap between Graham Number (4,532.66) and GLS Growth (34,298.37). When the models are this far apart the "fair value" is really a range, and the margin of safety above should be read with that range in mind.

The nightly engine files NIVF under Value: positive earnings at a P/E of 18 or less.

Nine valuation models for NIVF

Each model turns the latest filed numbers into a value per share; the GLS fair value is the simple average of the ones that produce a positive number. The last two rows are shown for reference and never enter the average. The Quote page lets you switch any model off and add your own margin of safety.

ModelValuevs priceWhat it measures
DCF--Present value of the projected free cash flows, discounted at the cost of capital; no value tonight
Graham Number4,532.66+1812963%The most a defensive investor pays for the earnings and book value per share
Graham Growth32,046.12+12818347%Graham's growth formula: EPS × (8.5 + 2 × growth), adjusted for bond yields
Lynch14,006.17+5602368%EPS × the earnings growth rate (PEG of 1), growth capped at 25%
GLS Growth34,298.37+13719247%EPS compounded ten years at the blended growth rate, discounted back at 15% a year
10 Cap--Owner's earnings (operating cash flow less maintenance capex) capitalised at 10%; no value tonight
Payback Time--Eight years of compounded free cash flow: the price at which the business pays for itself; no value tonight
DDM--Dividend discount model: next year's dividend ÷ (10% − 3% growth); needs a dividend; no value tonight
EPV6,224.96+2489886%Earnings power value: current EPS capitalised at 9% with no growth
Zombie (liquidation)41.00+16301%Current assets less all liabilities, per share: the balance-sheet floor. Not in the average
Wall St target0.0000-100%Analysts' average 12-month price target. Not in the average

Quality and financial health

NewGenIvf Group Limited scores 5 of 9 on the Piotroski F-score: a middling result that falls one point short of the Sunday Scan's "6 or more" rule. Some of the nine tests on profitability, leverage and efficiency are failed, so the accounts are worth a look before selling a put on the name. A GLS Moat score of 3.6/10 is a weak reading: the ten-year history the score grades (revenue, EPS, book value, margins, cash flow, share count, ROIC) has not been steady, so the Moat part of the Wheel Score contributes little.

Returns on capital are high - ROIC 31.4%, ROE 37.1%, ROA 30.2% - with debt at 0.18 times equity and negative free cash flow.

NewGenIvf Group Limited pays no dividend, so the DDM model does not apply and a covered-call holder earns only the premium and any price gain.

Institutional ownership scores 1/10, insider activity 10/10 and Congressional trading 5/10 on the GLS smart-money scales.

Piotroski F-score5 / 9ROIC31.4%
GLS Moat3.6 / 10ROE37.1%
Debt / equity0.18ROA30.2%
Free-cash-flow yield0.0%Payout ratio0%
Institutions1 / 10Insiders · Congress10 · 5 / 10

Wheel Score 39: No options

No options are listed on NewGenIvf Group Limited in our nightly snapshot. The Wheel Score is therefore capped at 39 (it reads 39) and the stock is left out of every options screen; the fair value and health figures above are still useful for a plain stock position.

Volume runs at 7.0M shares a day on a market cap of $4K, with a beta of -0.04 - a low beta, so day-to-day moves are smaller than the market's; the Stability part of the Wheel Score gives that 14 of 20.

PartPointsFrom
Value25 / 25100% margin of safety
Health11 / 20Piotroski 5/9
Moat5 / 15moat 3.6/10
Premium0 / 20no option data
Stability14 / 207.0M shares/day, $0M cap, beta -0.04

The Wheel Score ranks ~7,400 US stocks for selling cash-secured puts and covered calls; it is updated nightly and is not a recommendation. The walkthrough lesson shows how the score fits into a trade, start to finish.

Upcoming events

No upcoming earnings date is recorded for NIVF in the nightly calendar.

Earnings, dividend, IPO, split and economic calendars for the whole market, filterable to your watchlists.

Similar stocks in Medical - Care Facilities

The 12 companies below are the closest to NewGenIvf Group Limited by market cap within the Medical - Care Facilities industry, each with its own fact sheet; the Compare page puts up to eight of them side by side.

StockCloseFair valueMoSWheelMkt cap
MNDR
Mobile-health Network Solutions Class A Ordinary Shares
1.09--33No options$27K
CCM
Concord Medical Services Holdings Limited
3.62--34No options$524K
FOXO
FOXO Technologies Inc.
0.11000.8043+86%39No options$1M
PMHS
Polomar Health Services, Inc.
0.12500.0935-34%17No options$4M
AIDX
20/20 Biolabs Inc.
0.2751--30No options$4M
RHEP
Regional Health Properties, Inc.
1.0231,975.90+100%39No options$4M
BMGL
Basel Medical Group Ltd Ordinary Shares
3.91--30No options$6M
HLYK
HealthLynked Corp.
2.20--25No options$6M
BICX
BioCorRx Inc.
0.2500--28No options$7M
AMS
American Shared Hospital Services
1.266.91+82%39No options$8M
SYRA
Syra Health Corp. Class A Common Stock
0.84300.2255-274%14No options$10M
RHEPB
Regional Health Properties, Inc.
6.2539,547.42+100%39No options$11M

⚖ Compare NIVF with 7 of them   All Healthcare stocks →

Screen the whole market the same way

A free GLS Equity account gets you nightly fair value and the Wheel Score on ~7,400 US stocks, a watchlist, the scanner preview and the Sunday Scan - the same eight-rule screen, emailed every week. Pro adds the full put and call scanners, unlimited watchlists with alerts and the trade journal.

Start free See the Sunday Scan

Questions about NIVF

Is NIVF undervalued right now?

By the GLS models, yes: at 0.2500 the stock is 100% below the average fair value of 18,221.66 (data as of 16 Oct 2026). Whether the discount is deserved is the question to research next.

What is the Wheel Score of NIVF and what does it mean?

NIVF has no listed options in our nightly snapshot, so it cannot be wheeled; its Wheel Score is capped at 39 and shown as "No options".

What is the GLS fair value for NIVF?

18,221.66 per share as of 16 Oct 2026 - the simple average of the 5 valuation models (out of nine: DCF, Graham Number, Graham Growth, Lynch, GLS Growth, 10 Cap, Payback Time, DDM and EPV) that produced a positive value. The models run every night on the latest filings; the Quote page lets you switch any of them off and add a margin of safety of your own.

When does NewGenIvf Group Limited report earnings next?

No upcoming earnings date is recorded for NIVF in our calendar as of 16 Oct 2026; the Calendars page is refreshed every morning.

Does NIVF have listed options, and how liquid are they?

No. The nightly options snapshot found no listed contracts on NIVF, so the wheel strategy cannot be run on it and the Wheel Score is capped at 39.

Data as of 16 Oct 2026: prices and fundamentals from Financial Modeling Prep, option data from Polygon; valuations, scores and the Wheel Score by GLS Equity's models, run nightly. Prices in USD; the close shown is the previous session's. Everything on this page is general information produced by automated models from third-party data - not a recommendation to buy, sell or trade any security or option, and not financial advice. Past performance is not indicative of future results. GLS Equity provides data and tools, not financial advice.